Shots:
- Royalty Pharma will pay Neurimmune up to $425M, incl. $125M upfront, in exchange for a 3% to 4% royalty on worldwide net sales of AstraZeneca’s cliramitug
- Royalty Pharma will pay Neurimmune an additional $125M in cash in Q1’27, with the remaining $175M contingent on the achievement of specified clinical & regulatory milestones
- Cliramitug is a TTR-fibril-depleting antibody designed to remove amyloid deposits in pts with TTR amyloidosis with cardiomyopathy, which is being assessed in the P-III (DepleTTR-CM) trial, with results expected in 2028
Ref: Globenewswire | Image: Royalty Pharma, Neurimmune, & AstraZeneca | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
